Stephan Siegel

USPTO Granted Patents = 12 (Patent Applications = 12)

EPO Patents = 9 (Patent Applications = 21)

Average Co-Inventor Count = 9.3

ph-index = 3

Forward Citations = 24(Granted Patents)

Company Filing History:

7 out of 721

Bayer Intellectual Property Gmbh

patents

3 out of 12,157

Bayer Aktiengesellschaft

patents

3 out of 378

Bayer Pharma Aktiengesellschaft

patents

4. 2 out of 1,206

Dana-farber-cancer Institute Inc.

patents

5. 2 out of 443

The Broad Institute, Inc.

patents

6. 1 out of 2

Bayer Pharma Aktiengessellschaft

patents

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

12 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12403135 - 4H-pyrrolo[3,2-c]pyridin-4-one derivatives (2025-09-02),

2. 11339157 - 4H-pyrrolo[3,2-c]pyridin-4-one derivatives (2022-05-24),

3. 11161825 - 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamides (2021-11-02),

4. 9890147 - 2,3-benzodiazepines (2018-02-13),

5. 9663523 - BET protein-inhibiting 5-aryltriazoleazepines (2017-05-30),

6. 9434731 - Imidazo-, pyrazolopyrazines and imidazotriazines and their use (2016-09-06),

7. 9051323 - Substituted imidazopyrimidines and triazolopyrimidines (2015-06-09),

8. 8664246 - Substituted pyridines, and use thereof as GSK3 inhibitors (2014-03-04),

9. 8476267 - Imidazo-, pyrazolopyrazines and imidazotriazines and their use (2013-07-02),

10. 8436003 - Substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines (2013-05-07),

11. 8273752 - Substituted imidazopyrimidines and triazolopyrimidines (2012-09-25),

12. 8198267 - Substituted oxazolidinones and their use (2012-06-12),

Title: The Innovative Contributions of Stephan Siegel

Introduction

Stephan Siegel is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of hyperproliferative diseases. With a total of 12 patents to his name, Siegel's work has had a substantial impact on medical research and development.

Latest Patents

Among his latest patents are the 4H-pyrrolo[3,2-c]pyridin-4-one derivatives. These compounds are designed for use in the treatment or prophylaxis of diseases, specifically targeting hyperproliferative diseases and disorders responsive to the induction of cell death. This includes haematological tumours, solid tumours, and metastases that harbor a mutant EGFR with exon 19 or 21 mutations. Additionally, he has developed processes for the production of these compounds and their use as pharmaceuticals.

Career Highlights

Stephan Siegel has worked with notable companies such as Bayer Intellectual Property GmbH and Bayer Aktiengesellschaft. His experience in these organizations has allowed him to refine his expertise in patent development and pharmaceutical innovation.

Collaborations

Throughout his career, Siegel has collaborated with esteemed colleagues, including Mark Jean Gnoth and Ulrich Rester. These partnerships have further enhanced his contributions to the field.

Conclusion

Stephan Siegel's innovative work and numerous patents underscore his importance in the pharmaceutical industry. His dedication to advancing medical treatments continues to make a significant difference in the lives of many.

This text is generated by artificial intelligence and may not be accurate.